within Pharmacolibrary.Drugs.ATC.R;

model R05CB06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.79,
    Cl             = 1.3833333333333333,
    adminDuration  = 600,
    adminMass      = 0.03,
    adminCount     = 1,
    Vd             = 0.055,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008,
    Tlag           = 900
  );

  annotation(Documentation(
    info ="<html><body><p>Ambroxol is a mucolytic agent used primarily in the treatment of respiratory diseases associated with viscid or excessive mucus production. It works by breaking down mucus to make it less viscous and easier to clear from the airways. Ambroxol is approved and widely used in many countries in both adult and pediatric populations, commonly administered as oral tablets, syrups, or intravenous injections.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in healthy adult volunteers following a single oral dose.</p><h4>References</h4><ol><li><p>Yang, YG, et al., &amp; Zhang, M (2015). Pharmacokinetics of ambroxol and clenbuterol tablets in healthy Chinese volunteers. <i>International journal of clinical and experimental medicine</i> 8(10) 18744–18750. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26770490/&quot;>https://pubmed.ncbi.nlm.nih.gov/26770490</a></p></li><li><p>Jiang, B, et al., &amp; Ruan, ZR (2014). Pharmacokinetics and bioequivalence study of three oral formulations of ambroxol 30 mg: a randomized, three-period crossover comparison in healthy volunteers. <i>International journal of clinical pharmacology and therapeutics</i> 52(10) 920–926. DOI:<a href=&quot;https://doi.org/10.5414/CP202156&quot;>10.5414/CP202156</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25207547/&quot;>https://pubmed.ncbi.nlm.nih.gov/25207547</a></p></li><li><p>Wang, Y, et al., &amp; Ding, L (2018). Pharmacokinetics and safety of salbutamol/ambroxol fixed-dose combination granules in healthy Chinese subjects . <i>International journal of clinical pharmacology and therapeutics</i> 56(12) 597–603. DOI:<a href=&quot;https://doi.org/10.5414/CP203212&quot;>10.5414/CP203212</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30232958/&quot;>https://pubmed.ncbi.nlm.nih.gov/30232958</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R05CB06;
